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We agree with Dr. Addeo and Dr. Banna when they 
emphasize that the biology of non-small cell lung cancer 
(NSCLC) is complex, and that a single biomarker is 
probably not exhaustive in order to optimally predict 
(either positively or negatively) the potential efficacy of 
immune checkpoint inhibitors. However, in our opinion, 
a clear distinction should be made between open areas 
of interest for clinical research and the use of drugs that 
can be recommended in routine clinical practice. At 
the moment, in fact, the evidence supporting the use of 
immune checkpoint inhibitors in patients with epidermal 
growth factor receptor (EGFR)- or anaplastic lymphoma 
kinase (ALK)-positive NSCLC in clinical practice is 
honestly weak. 
Oncogene-driven NSCLC cases can show both innate 
and adaptive resistance to immunotherapy (1,2). As for 
innate resistance, compared to typical smoking-associated 
cases, EGFR- or ALK-positive tumors are characterized, 
on average, by a lower somatic mutational burden, and this 
might imply that tumors are less immunogenic, with scarcity 
of tumor infiltrating lymphocytes and presence of tumor-
infiltrating regulatory T cells (3). As for adaptive resistance, 
treatment with a tyrosine kinase inhibitor (TKI) can induce 
apoptosis of tumor cells, leading to tumor infiltration by 
immune cells and cytokine production, including cytotoxic 
enzymes (perforin and granzyme) and pro-inflammatory 
cytokines that could interfere with immune response.
Of course, we acknowledge that this “immune-
challenging” biological scenario could substantially change 
when the disease becomes no longer sensitive to tyrosine 
kinase inhibition. Pretreated, resistant disease is reasonably 
characterized by changes in tumor dominant pathways, 
294-296
Cons: should immunotherapy be incorporated in the treatment of 
oncogene-driven lung cancer?
Giulio Metro1, Massimo Di Maio2
1Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy; 2Medical Oncology, A.O. Ordine 
Mauriziano, Department of Oncology, University of Torino, Torino, Italy
Correspondence to: Giulio Metro, MD. Staff Physician, Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, 
via Dottori, 1, 06156, Perugia, Italy. Email: giulio.metro@yahoo.com.
Related to: Addeo A, Banna GL. PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer? Transl Lung 
Cancer Res 2018;7:S283-6.
Metro G, Di Maio M. CONS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer? Transl Lung Cancer Res 
2018;7:S290-3.
Addeo A, Banna GL. PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer? Transl Lung Cancer Res 
2018;7:S287-9.
Submitted May 26, 2018. Accepted for publication Jun 30, 2018.
doi: 10.21037/tlcr.2018.07.12
View this article at: http://dx.doi.org/10.21037/tlcr.2018.07.12
Controversies on Lung Cancer: Pros and Cons
Editor’s Note:
In the era of personalized medicine, a critical appraisal new developments and controversies are essential in order to 
derived tailored approaches. In addition to its educative aspect, we expect these discussions to help younger researchers to 
refine their own research strategies.
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along with changes in the interplay between tumor cells, 
immune cells and surrounding microenvironment (4). 
Consequently, we believe that preclinical and clinical 
research aimed to better define the role of immune 
checkpoint inhibitors (both as single-agents and as part of 
combination) in patients with oncogene-addicted NSCLC 
should be especially encouraged in pretreated patients. 
So, we agree with Dr. Addeo and Dr. Banna conclusions, 
when they state that immune checkpoint inhibitors deserve 
further investigation. However, we believe that not all trial 
designs are equally worthwhile. Trials investigating the role 
of immune checkpoint inhibitors in patients that would 
be still eligible for targeted drugs as part of their standard 
management (for instance, the trial NCT02879994, testing 
the anti-PD-1 pembrolizumab in patients with EGFR-
mutated, TKI-naïve, PD-L1-positive advanced NSCLC) 
do not seem particularly intriguing, and are not necessarily 
a valuable opportunity for participating patients (5). On 
the contrary, we look with interest at several ongoing 
trials, testing immune checkpoint inhibitors in pretreated, 
EGFR-mutated cases. For instance, Checkmate 722 
(NCT02864251) is a phase 3 trial testing the role of two 
combination regimens (platinum-based chemotherapy 
+ nivolumab and nivolumab + ipilimumab) in patients 
with EGFR-mutated T790M-negative cases, who have 
failed treatment with a TKI. The trial compares the two 
above mentioned experimental combinations with the 
current standard for these patients, that is platinum-based 
chemotherapy. Another randomized trial (NCT03091491) 
is comparing single-agent nivolumab with a combination 
of nivolumab plus ipilimumab in patients with advanced 
EGFR-mutated NSCLC who have failed one line of 
standard EGFR-TKI treatment and no more than one line 
of chemotherapy regimen, allowing the administration of 
a third generation EGFR-TKI for patients with acquired 
T790M mutation. Consequently, these patients have 
already received the targeted treatments available in 
clinical practice. Considering that biology and mechanisms 
of resistance of these tumors are different from naïve 
cases, there is room to explore the potential efficacy of 
immunotherapy.  
On the other hand, if the aim of this controversy is to 
give an educational message for current clinical practice 
and not for investigational issues, we should honestly 
admit that, at least to date, the evidence supporting the 
role of immune checkpoint inhibitors in oncogene-driven 
NSCLC is disappointing (6). We perfectly agree with Dr. 
Addeo and Dr. Banna that objective responses have been 
described in a minority of these subjects, but unfortunately, 
at the moment, we completely lack predictive biomarkers 
of sensitivity to PD-1-/PD-L1-inhibitors in NSCLC cases 
with EGFR mutations (7). Therefore, we strongly believe 
that sustainability should be a priority guiding treatment 
choices in clinical practice, and every effort should be made 
to identify the best candidates for each therapy. 
In 2018, looking at the whole body of evidence, single-
agent immune checkpoint inhibitors currently available 
in clinical practice are definitely not the best choice in 
oncogene-driven NSCLC patients. 
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